---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036847"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:18:40.321753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Metagenomi reports FY2023 net loss of $68.3M; Hemophilia A NHP proof of concept achieved

## Summary
- Net loss $68.3M in FY2023; collaboration revenue $44.8M, up from $17.2M in 2022.
- Cash and equivalents $271.2M at Dec 31, 2023; plus $81.1M net IPO proceeds in Feb 2024.
- Hemophilia A program achieved NHP proof of concept; development candidate nomination expected mid-2024.
- Demonstrated CAST system for >10,000 bp targeted integrations and SMART base editors as small as 623 amino acids.
- Cash runway supports 2 INDs and 2 additional development candidate nominations.

## SEC filing metadata
- accession: 0000950170-24-036847
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/0000950170-24-036847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/mgx-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036847
- JSON: https://secwatch.observer/filing/0000950170-24-036847.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036847.txt

## Key facts
- Earnings Releases
  Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2023.
  - Period: the full year ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, Metagenomi, Inc. announced its financial results for the year ended December 31, 2023 and additional business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785279/000095017024036847/0000950170-24-036847-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.